ImmuCell Corp (ICCC)
5.05
0.00 (0.00%)
USD |
NASDAQ |
Apr 18, 16:00
5.06
+0.01
(+0.20%)
After-Hours: 20:00
ImmuCell Revenue (Quarterly): 5.096M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 5.096M |
| September 30, 2023 | 5.396M |
| June 30, 2023 | 3.533M |
| March 31, 2023 | 3.446M |
| December 31, 2022 | 3.911M |
| September 30, 2022 | 4.796M |
| June 30, 2022 | 3.861M |
| March 31, 2022 | 6.000M |
| December 31, 2021 | 5.444M |
| September 30, 2021 | 5.150M |
| June 30, 2021 | 4.542M |
| March 31, 2021 | 4.107M |
| December 31, 2020 | 3.743M |
| September 30, 2020 | 3.722M |
| June 30, 2020 | 2.966M |
| March 31, 2020 | 4.910M |
| December 31, 2019 | 3.632M |
| September 30, 2019 | 2.970M |
| June 30, 2019 | 2.710M |
| March 31, 2019 | 4.411M |
| December 31, 2018 | 2.937M |
| September 30, 2018 | 2.154M |
| June 30, 2018 | 3.014M |
| March 31, 2018 | 2.881M |
| December 31, 2017 | 3.133M |
| Date | Value |
|---|---|
| September 30, 2017 | 2.005M |
| June 30, 2017 | 1.750M |
| March 31, 2017 | 3.544M |
| December 31, 2016 | 2.214M |
| September 30, 2016 | 1.968M |
| June 30, 2016 | 2.376M |
| March 31, 2016 | 2.986M |
| December 31, 2015 | 2.694M |
| September 30, 2015 | 2.472M |
| June 30, 2015 | 1.960M |
| March 31, 2015 | 3.102M |
| December 31, 2014 | 2.205M |
| September 30, 2014 | 1.770M |
| June 30, 2014 | 1.540M |
| March 31, 2014 | 2.082M |
| December 31, 2013 | 1.559M |
| September 30, 2013 | 1.235M |
| June 30, 2013 | 1.366M |
| March 31, 2013 | 1.847M |
| December 31, 2012 | 1.421M |
| September 30, 2012 | 1.077M |
| June 30, 2012 | 1.175M |
| March 31, 2012 | 1.717M |
| December 31, 2011 | 1.304M |
| September 30, 2011 | 1.004M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
2.710M
Minimum
Jun 2019
6.000M
Maximum
Mar 2022
4.207M
Average
3.911M
Median
Dec 2022
Revenue (Quarterly) Benchmarks
| NovaBay Pharmaceuticals Inc | 3.727M |
| Palatin Technologies Inc | 2.034M |
| iBio Inc | -- |
| Theriva Biologics Inc | -- |
| Ampio Pharmaceuticals Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -1.140M |
| Total Expenses (Quarterly) | 6.100M |
| EPS Diluted (Quarterly) | -0.15 |
| Enterprise Value | 50.13M |
| Gross Profit Margin (Quarterly) | 24.68% |
| Profit Margin (Quarterly) | -22.37% |
| Earnings Yield | -14.85% |
| Normalized Earnings Yield | -15.57 |